Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PRD001 study in healthy adults and adults with mild hyper-LDL-cholesterolemia and mild fatty liver
jRCT2071250016Phase 1Recruiting
- Sponsor
- PRD Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRD001 in familial hypercholesterolemia (FH), hypercholesterolemia and steatosis (6 arms), sponsored by PRD Therapeutics. Primary endpoint: Safety and tolerability. Started Jun 2025; status: recruiting.
02
Drugs
PRD001
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemiasteatosis
Beyond the preview
Go deeper on jRCT2071250016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250016.